Patented Medicine Prices Review Board Imposes Deadline for Motions for Leave to Intervene in the Redetermination of Board Decisions Regarding the Excessive Pricing of Soliris Dated September 27 and November 8, 2017

The Patented Medicine Prices Review Board will hold a public rehearing in the matter of the price of the patented medicine Soliris, and Alexion Pharmaceuticals Inc., the pharmaceutical company that holds the patent for Soliris and sells the medicine in Canada. Отсюда - | Перевод - Яндекс.

Comments are closed.